Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
Amit Kulkarni(University of Minnesota), Arpit Rao(Baylor College of Medicine), Charles J. Ryan(University of Minnesota), Anthony Tholkes(University of Minnesota), Surbhi Shah(WinnMed), Nooreen Rubin(Masonic Cancer Center), Anna E. Prizment(University of Minnesota), Pamela L. Lutsey(University of Minnesota)
Cited by 31
Related Papers
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Heart Disease and Stroke Statistics—2021 Update
|Circulation|2021|5.7k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k